Your session is about to expire
← Back to Search
Antibiotic
JNJ-32729463 Open-Label for Community-acquired Pneumonia
Phase 2
Waitlist Available
Research Sponsored by Furiex Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).
Eligible Conditions
- Community-acquired Pneumonia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: JNJ-32729463 Open-LabelExperimental Treatment1 Intervention
subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
Group II: JNJ-32729463Experimental Treatment1 Intervention
Group III: moxifloxacinActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JNJ-32729463
2010
Completed Phase 2
~170
Find a Location
Who is running the clinical trial?
Furiex Pharmaceuticals, IncLead Sponsor
5 Previous Clinical Trials
3,678 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger